Ionic Silver Complex Designed for Use in Humans Receives U.S. Patent
The use of ionic silver in human use goes back hundreds -- indeed thousands -- of years. During the past century, it was predominantly used in the medical field in the forms of silver nitrate and colloidal silver -- which has been increasingly used during the past few decades. In Europe, pharmacists have silver compounds listed in their desk references for many uses. In the U.S., recent university studies are suggesting far-reaching potential benefits of ionic silver. The past few years have seen a surge in the number of medical and industrial products that deliver silver ions, for a wide range of uses.
Whether colloidal silver, silver-impregnated bandages and wound dressings, coatings for surfaces in hospitals and homes, or catheters and IV needles, the goal is the controlled delivery of silver as ions. Delivery is a function of the bonding agent -- the complexing or compounding agent -- which controls the release of the silver as ions in the given environment at the desired rate.
Invision has already incorporated the patented technology into a water-based dietary supplement called Silver 100. The key ingredient in Silver 100 is called Opti-Silver -- silver ions complexed with citrate and potassium for optimal delivery of silver ions in the human body.
According to Jay Newman, president of Invision International, the patented technology represents a quantum leap in delivering silver ions internally to the human body. "We chose citrate because we believe it is, by far, the ideal carrier for efficient delivery of silver ions for human use," Newman said, "based on years of effort and research that required millions of dollars invested." Potassium is used as the counter-ion for equilibrium in the water. "Silver 100 uses all-natural ingredients and is intended to provide an entirely safe product that introduces less silver to the body than what may exist in a person's average drinking water intake -- but as active ions."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.